A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

Inclusion Criteria:

• Provision of signed and dated, written informed consent prior to any study-specificprocedures.

• Participants with suitable veins for cannulation or repeated venipuncture.

• Have a body mass index (BMI) between 18 and 32 kilograms per meter squared (kg/m2)inclusive and weigh at least 50 kilograms (kg) at Screening.

Exclusion Criteria:

• History of any clinically important disease or disorder which, in the opinion of theinvestigator, may either put the participant at risk.

• History or presence of gastrointestinal, hepatic, or renal disease or any othercondition known to interfere with absorption, distribution, metabolism, or excretionof drugs.

• Any clinically important illness, medical/surgical procedure, or trauma within 4weeks of the first administration of study intervention.

• Any clinically important abnormalities in clinical chemistry, coagulation,hematology, or urinalysis results.

• Any positive result at the Screening Visit for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV), or humanimmunodeficiency virus (HIV).

• Abnormal vital signs, after 10 minutes supine rest, at the Screening Visit and/oradmission to the Clinical Unit (Day -2).

• Any clinically important abnormalities in rhythm, conduction, or morphology of theresting 12-lead safety ECG.

• History of severe allergy/hypersensitivity or ongoing clinically importantallergy/hypersensitivity.

• History of hypersensitivity to DPP4 inhibitors, as judged by the investigator, orhistory of hypersensitivity to drugs with a similar chemical structure or class toDPP4 inhibitors.

• History of severe dermatological disorders, eg, bullous pemphigoid orStevens-Johnson syndrome, as judged by the investigator.

• Participants who have previously received AZD2389 within the last 12 months prior tothe Screening Visit.

• Known hypersensitivity or previous adverse events associated with midazolam,caffeine, or bupropion.